You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,420,645


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,420,645 protect, and when does it expire?

Patent 8,420,645 protects TABRECTA and is included in one NDA.

This patent has forty-nine patent family members in thirty-one countries.

Summary for Patent: 8,420,645
Title:Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,- 4]triazin-2-yl]benzamide and processes related to preparing the same
Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin- -2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-- 2-yl]benzamide, and salts thereof.
Inventor(s): Weng; Lingkai (Malvern, PA), Qiao; Lei (Downingtown, PA), Zhou; Jiacheng (Newark, DE), Liu; Pingli (Newark, DE), Pan; Yongchun (Newark, DE)
Assignee: Incyte Corporation (Wilmington, DE)
Application Number:12/469,360
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,420,645: A Detailed Analysis

Introduction

United States Patent 8,420,645, like any other patent, is a complex document that outlines the invention, its claims, and the scope of protection it offers. To analyze this patent, we need to delve into its claims, the patent landscape, and relevant legal and technical aspects.

Patent Overview

  • Patent Number: 8,420,645
  • Issue Date: This information is not provided in the sources, but it can be found through the USPTO database.
  • Inventors and Assignees: Similarly, this specific information is not provided, but it is crucial for understanding the ownership and development history of the patent.

Claims Analysis

Claim Construction

The claims of a patent are its most critical component, as they define the scope of the invention. Claim construction is a matter of law, reviewed de novo by the courts[2].

  • Independent and Dependent Claims: Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims. The length and count of independent claims can be metrics for measuring patent scope[3].

Claim Scope and Clarity

The scope and clarity of claims are vital for patent quality. Broad or unclear claims can lead to increased licensing and litigation costs, potentially hindering innovation. For example, software patents have been criticized for their broad and unclear claims, which can impede innovation[3].

Patent Landscape

Related Patents and Prior Art

Understanding the patent landscape involves identifying related patents, prior art, and any ongoing or past litigation.

  • Prior Art: This includes all publicly available information that existed before the patent application was filed. Prior art can be used to challenge the validity of a patent.
  • Related Patents: Patents in the same family or those that claim priority to the same application can have overlapping subject matter. This is relevant in cases of double patenting and terminal disclaimers[1].

Double Patenting and Terminal Disclaimers

Double patenting occurs when two or more patents claim the same invention. Terminal disclaimers are used to prevent this by ensuring that the later-expiring patent does not extend beyond the expiration date of the earlier patent.

  • Patent Term Adjustment (PTA) and Patent Term Extension (PTE): PTA and PTE can extend the life of a patent, but they are treated differently in the context of double patenting. PTA is added after the original expiration date, while PTE is calculated from the original expiration date or disclaimed date[1].

Legal Considerations

Covered Business Method (CBM) Review

If the patent is related to business methods, it may be subject to CBM review under the Leahy-Smith America Invents Act. This review can challenge the validity of patents directed to performing data processing or other business methods[4].

Inter Partes Review (IPR)

IPR is another mechanism for challenging patent validity. It involves a review by the Patent Trial and Appeal Board (PTAB) to determine if the claims of a patent are unpatentable. The Board's decision can be appealed to the Federal Circuit[2].

Technical Aspects

Invention Description

The patent specification describes how to make and use the invention. It must be enabling, meaning it must teach a skilled artisan how to practice the invention without undue experimentation[5].

Litigation and Enforcement

Patent Infringement

If the patent owner alleges infringement, the case would involve analyzing whether the accused product or method falls within the scope of the claims. This often involves claim construction and determining whether the accused product meets all the elements of the claims.

Case Law and Precedents

  • Federal Circuit Decisions: Decisions from the Federal Circuit, such as Novartis AG v. Ezra Ventures LLC and Eli Lilly and Company v. Teva Pharmaceuticals, provide guidance on patent term adjustments, double patenting, and claim construction[1][2].

Key Takeaways

  • Claims Define the Scope: The claims are the heart of the patent and define what is protected.
  • Patent Term Adjustments: PTA and PTE extend patent life differently and are treated distinctively in legal analyses.
  • Legal Challenges: Patents can be challenged through CBM review, IPR, and litigation.
  • Technical Enablement: The patent specification must be enabling to support the claims.
  • Litigation: Patent infringement cases hinge on claim construction and whether the accused product meets all claim elements.

FAQs

Q1: What is the difference between Patent Term Adjustment (PTA) and Patent Term Extension (PTE)?

  • PTA is added to the original expiration date of a patent, while PTE is calculated from the original expiration date or disclaimed date[1].

Q2: How are terminal disclaimers used in patent law?

  • Terminal disclaimers are used to prevent double patenting by ensuring that a later-expiring patent does not extend beyond the expiration date of an earlier patent[1].

Q3: What is Covered Business Method (CBM) review?

  • CBM review is a process under the Leahy-Smith America Invents Act to challenge the validity of patents directed to performing data processing or other business methods[4].

Q4: How is claim construction reviewed in patent litigation?

  • Claim construction is reviewed de novo by the courts, and it is a matter of law[2].

Q5: What makes a patent specification enabling?

  • A patent specification is enabling if it teaches a skilled artisan how to make and use the invention without undue experimentation[5].

Sources

  1. Duanemorris.com: Patent Term Adjustment and Patent Term Extension Analyzed Differently in Consideration of Double Patenting.
  2. CAFC.uscourts.gov: Eli Lilly and Company v. Teva Pharmaceuticals.
  3. Hoover.org: Patent Claims and Patent Scope.
  4. Hklaw.com: Healthcare Data Analytics Patent Subject to “CBM” Review at USPTO.
  5. Supremecourt.gov: Amgen Brief for Petitioners.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,420,645

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharm TABRECTA capmatinib hydrochloride TABLET;ORAL 213591-001 May 6, 2020 RX Yes No ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Novartis Pharm TABRECTA capmatinib hydrochloride TABLET;ORAL 213591-002 May 6, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,420,645

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 071873 ⤷  Subscribe
Argentina 111428 ⤷  Subscribe
Argentina 123240 ⤷  Subscribe
Australia 2009249154 ⤷  Subscribe
Brazil PI0912882 ⤷  Subscribe
Canada 2724742 ⤷  Subscribe
Chile 2009001250 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.